WuXi PharmaTech, China’s largest CRO, has completed its $3.3 billion privatization and de-listed its shares from the New York Stock Exchange as of December 10. Ally Bridge Group was the initial named investor in the deal. It was joined by Boyu Capital, units of Ping An Insurance (Group) Co. of China, Singapore’s Temasek Holdings and Hillhouse Capital along with Dr. Ge Li, WuXi PharmaTech’s Chairman and CEO and other management executives. In 2006, just before WuXi IPO’d in New York, it had revenues of $70 million. In 2015, its revenues will be at least 12 times that.
